Safety and Efficacy Phase 2 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children

Learn more about:
Related Clinical Trial
Assessment of Adherence, Quality of Life, Clinical Response and Safety of Daily and Long-Acting Growth Hormone Therapy Impact of GH Measurements on GHD Diagnosis Fluids Administration During Combined Clonidine-Arginine Growth Hormone Stimulation Test Three Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly Free Fatty Acids, Body Weight, and Growth Hormones Secretion in Children A Single Dose Trial in Healthy Caucasians and Japanese Subjects Investigating the Pharmacokinetics of Somatropin Observational Study of Norditropin NordiFlex® With NordiFlex PenMate™ The Impact of the Use of Recombinant Human Growth Hormone on ADHD Characteristics in Children and Adolescents Constructing an Insulin-Like Growth Factor-based Prediction Model Peripheral Metabolic Effects of Somatostatin Chromosome 18 Clinical Research Center The Effect of Dietary Fat Load and Physical Exercise on the Flexibility and Partitioning of Ectopic Lipids. An Observational Study on Treatment Compliance by Children Treated With Growth Hormone A Single Dose Trial in Growth Hormone Deficient Children Investigating Safety, Pharmacokinetics and Pharmacodynamics of Long Acting Growth Hormone A Study to Compare the Uptake Into the Blood of Two Strengths of Somapacitan After Injection Under the Skin in Healthy Subjects Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese Growth Hormone as Add-on Treatment in Severe Fibromyalgia With Low IGF-1 Serum Levels (56 Characters) A Study to Optimize Growth Hormone Dosing in Children With Chronic Kidney Disease by Measuring IGF-1 Levels in Blood Safety and Efficacy of Long-term Somatropin Treatment in Adults Dose Study in Growth Hormone Deficient Adults Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083 r-hGH Liquid Multidose Versus Freeze-dried Multidose Bioequivalence Trial Effects of Growth Hormone and IGF-1 on Anabolic Signals and Stem Cell Recruitment in Human Skeletal Muscle Genotropin Study Assessing Use of Injection Pen Treatment With Recombinant Human Growth Hormone Genotonorm (Registered) In Children With Short Stature Secondary Validation of a Questionnaire That Identifies the Reasons for Non-adherence to Existing Growth Hormone Therapy Treatment of Children With Insufficient Secretion of Growth Hormone Metabolic and QOL Effects of GH Treatment in Patients With TBI and AGHD Anterior Pituitary Hormone Replacement in Traumatic Brain Injury Evolution Of Growth Rate In Children With Growth Retardation Due to Glucocorticosteroid Therapy And Treated By Genotonorm Transition Study: Growth Hormone Therapy In Partial Growth Hormone Deficient Adolescents MOD-4023 (Long-Lasting Human Growth Hormone (hGH)) Study in Growth Hormone Deficient Adults (GHDA) Safety and Efficacy Phase 2 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children Inter-Assay Growth Hormone and IGF-I Variability A Study to Evaluate Growth in Participants Treated With Somatropin (Nutropin) Using NuSpin Device Cardiovascular Risk in Growth Hormone Deficient Young Adult Males After Completing Growth Hormone Therapy Easypod United States User Trial National Cooperative Growth Study in CKD Low and Conventional Dose of Somatropin in Growth Hormone Deficient Adult Patients Practicability and Acceptability of Stylomax® in Children Growth Hormone’s Effect on the Cardiovascular System Exploring Interactions Between Growth Hormone and the Microbiome Pharmacokinetics and Pharmacodynamics of Long Acting Human Growth Hormone (hGH) Product (MOD-4023) in Healthy Caucasian and Japanese Volunteers A Phase 2, Safety and Dose-Finding Study in Treatment-Naive, Pre-Pubertal, Growth Hormone-Deficient Children Phase 1 Safety Study of ALRN-5281 in Healthy Subjects Safety, Pharmacokinetics and Pharmacodynamics Study of HL-032 in Healthy Male Volunteers Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients Growth Hormone and Chromosome 18q- and Abnormal Growth An Observational Study Validating a Score That Quantifies the Therapeutic Response to Treatment With Norditropin® Cross Over Convenience And Preference Study Of New Mark VII Compared To Genotropin Pen In Pediatric And Adult Subjects A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in Growth Hormone Deficient(GHD) Subjects During the Transition Phase From Childhood to Adulthood Study of TV-1106 in Growth Hormone-Deficient Adults Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children Long-Term Efficacy and Safety of Growth Hormone Replacement Therapy in Chronic Heart Failure Crossover Study to Assess the Safety and Pharmacokinetic of Pegylated Somatropin(PEG Somatropin) in GHD Children Study of an Extended-Release, Crystalline Formulation of Recombinant Human Growth Hormone (ALTU-238) in Growth Hormone Deficient Adults to Determine Pharmacokinetics, Pharmacodynamics, and Drug Safety Low Dose Growth Hormone (GH) on Insulin Sensitivity and Cortisol Production Rates Gene Expression in Monocytes of Growth Hormone Deficient Children Study of Pituitary Size and Function in Familial Dwarfism of Sindh Adipocyte Function and Somtropin Deficiency Sustained Release Formulation of Somatropin (rDNA Origin)for Injection Molecular Basis of the Growth Axis in Short Stature Cardiac and Skeletal Muscle Energy Metabolism in Abnormal Growth Hormone States The Effects of Growth Hormone (GH) on Lipid Depots The Effects of TZD on Fat Metabolism and Insulin Sensitivity in GH-Replaced GHD Patients Reference Values for Body Composition Parameters and IGF-I in the Adult NordiNet® International Outcome Study Effects of Growth Hormone Supplementation to Adults With Growth Hormone Deficient on Metabolism and Adipose Tissue Molecular Phenotype Sexually Dimorphic Effects of GHRH in Adult Growth Hormone Testing Metabolic Endocrinology and Growth Hormone in Adults Growth Hormone Treatment of Young Growth Hormone-Deficient Adults Safety and Efficacy of SR-hGH (Sustained-release Human Growth Hormone, Declage Inj.) rhGH Therapy on Hepatic Drug Metabolism Skeletal Muscle Effects of GH in Boys Assessment of Cardiovascular Risk Markers in Growth Hormone Deficient Patients With Nonsecreting Pituitary Adenomas Adipose Tissue and Serum Inflammation in GH Deficiency Adipose Tissue and Circulating Markers of Inflammation in GH Deficiency and Changes With GH Therapy

Brief Title

Safety and Efficacy Phase 2 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children

Official Title

Safety and Dose Finding Study of Different MOD-4023 Dose Levels Compared to Daily r-hGH Therapy in Pre-pubertal Growth Hormone Deficient Children

Brief Summary

      This is a phase II, open label, active-controlled, randomized safety and dose finding study
      of different MOD-4023 dose levels compared to daily r-hGH therapy in pre-pubertal growth
      hormone deficient children.
    


Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

Annual Height Velocity

Secondary Outcome

 Height Velocity at 6 Months

Condition

Pediatric Growth Hormone Deficiency

Intervention

MOD-4023

Study Arms / Comparison Groups

 MOD-4023 low dose
Description:  Once weekly subcutaneous injection of long acting r-hGH (MOD-4023)

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

56

Start Date

February 2012

Completion Date

July 2015

Primary Completion Date

July 2015

Eligibility Criteria

        Inclusion Criteria:

          1. Pre-pubertal child aged ≥ 3 yrs old and not above 10 years for girls or 11 years for
             boys with either isolated GHD, or GH insufficiency as part of multiple pituitary
             hormone deficiency.

          2. Confirmed diagnosis of GHD by two different GH provocation tests defined as a peak
             plasma GH level of ≤7 ng/ml, determined by central laboratory using a validated assay
             .

          3. Bone age (BA) is not older than chronological age and should be no greater than 9
             years for girls and 10 years for boys.

          4. Without prior exposure to any r-hGH therapy.

          5. Normal birth size, birth weight and length for gestational age

          6. Impaired height and height velocity defined as:

               1. Height (HT) of at least 2.0 standard deviations (SD) below the mean height for
                  chronological age (CA) and gender according to the standards from Prader et. al,
                  1989 , (HT SDS ≤ -2.0).

               2. Annualized height velocity (HV) below the 25th percentile for CA (HV <-0.7 SDS)
                  and gender according to the standards of Prader et al (1989). The interval
                  between two height measurements should be at least 6 months before inclusion.

          7. BMI must be within ±2 SD of mean BMI for the chronological age and sex according to
             the 2000 CDC standards.

          8. Baseline IGF-I level of at least 1 SD below the mean IGF-I level standardized for age
             and sex (IGF-I SDS ≤ -1.0) according to the central laboratory reference values;

          9. 12. Written informed consent of the parent or legal guardian of the patient and assent
             of the patient (if the patient can read).

        Exclusion Criteria:

          1. Children with past or present intracranial tumor growth as confirmed by an MRI scan
             (with contrast).

          2. History of radiation therapy or chemotherapy.

          3. Malnourished children defined as:

               1. Serum albumin below the lower limit of normal (LLN) according to the reference
                  ranges of central laboratory;

               2. Serum iron below the lower limit of normal (LLN) according to the reference
                  ranges of central laboratory;

               3. BMI < -2 SD for age and sex;

          4. Children with psychosocial dwarfism.

          5. Children born small for gestational age (SGA - birth weight and/or birth length < -2
             SD for gestational age).

          6. Presence of anti-hGH antibodies at screening.

          7. Any clinically significant abnormality likely to affect growth or the ability to
             evaluate growth, such as, but not limited to, chronic diseases like renal
             insufficiency, spinal cord irradiation, etc.

          8. Patients with diabetes mellitus.

          9. Patients with impaired fasting sugar (based on WHO; fasting blood sugar >110 mg/dl or
             6.1 mmol/l) after repeated blood analysis.

         10. Chromosomal abnormalities and medical "syndromes" (Turner's syndrome, Laron syndrome,
             Noonan syndrome, Prader-Willi Syndrome, Russell-Silver Syndrome, SHOX
             mutations/deletions and skeletal dysplasias), with the exception of septo-optic
             dysplasia.

         11. Closed epiphyses.

         12. Concomitant administration of other treatments that may have an effect on growth such
             as anabolic steroids and methylphenidate for attention deficit hyperactivity disorder
             (ADHD), with the exception of hormone replacement therapies (thyroxine,
             hydrocortisone, desmopressin (DDAVP))

         13. Children requiring glucocorticoid therapy (e.g. asthma) who are taking a dose of
             greater than 400 µg/d of inhaled budesonide or equivalents for longer than 1 month
             during a calendar year.

         14. Major medical conditions and/or presence of contraindication to r-hGH treatment.

         15. Known or suspected HIV-positive patient, or patient with advanced diseases such as
             AIDS or tuberculosis.

         16. Drug, substance, or alcohol abuse.

         17. Known hypersensitivity to the components of study medication.

         18. Other causes of short stature such as coeliac disease, hypothyroidism and rickets.

         19. The patient and/or the parent/legal guardian are likely to be non-compliant in respect
             to study conduct.

         20. Participation in any other trial of an investigational agent within 30 days prior to
             Screening.
      

Gender

All

Ages

3 Years - 11 Years

Accepts Healthy Volunteers

No

Contacts

Zvi Zadik, MD, , 

Location Countries

Greece

Location Countries

Greece

Administrative Informations


NCT ID

NCT01592500

Organization ID

CP-4-004

Secondary IDs

2011-004553-60

Responsible Party

Sponsor

Study Sponsor

OPKO Health, Inc.


Study Sponsor

Zvi Zadik, MD, Principal Investigator, Kaplan Medical Center, Israel


Verification Date

January 2020